Schrödinger Spins Out Tectora Therapeutics in $55M Immunology Licensing Deal
- On September 9, 2026, Schrödinger announced a licensing and collaboration agreement with Tectora Therapeutics, a new immunology/inflammation biotech it co-founded with NEA and RA Capital Management.
- Schrödinger licensed two early-stage small-molecule programs, SDGR-4594 and SDGR-8139, to Tectora for an equity stake plus potential future milestone payments and royalties.
- Tectora concurrently closed a $55 million Series A financing from NEA and RA Capital to fund preclinical work on the programs.
- Tectora will use Schrödinger's computational drug discovery platform to advance the licensed assets toward clinical candidates.
- The deal lets Schrödinger monetize and advance internal pipeline assets via an external company while retaining equity upside.
Schrödinger is monetizing its own discovery engine here, not just licensing it to others — a meaningful shift for a company whose story has long been 'platform, not pipeline.' Spinning SDGR-4594 and SDGR-8139 out to a VC-backed shell instead of advancing them in-house is capital-efficiency logic: Schrödinger keeps equity and royalty upside without funding preclinical burn off its own balance sheet, while NEA and RA Capital absorb the binary risk. The equity-plus-milestones structure, instead of a straight license fee, signals that early discovery-stage assets are hard to price for cash right now — everyone's betting on the come. Watch for more computational-discovery shops (Recursion, Insitro, Isomorphic) following this playbook: spin out rather than sell or self-fund, and let Series A investors underwrite the translational risk.
Schrödinger births new immunology and inflammation biotech, Tectora Therapeutics ↗